NASDAQ:CAMP CAMP4 Therapeutics (CAMP) Stock Price, News & Analysis $3.96 +0.06 (+1.54%) Closing price 04:00 PM EasternExtended Trading$4.13 +0.17 (+4.19%) As of 04:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About CAMP4 Therapeutics Stock (NASDAQ:CAMP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CAMP4 Therapeutics alerts:Sign Up Key Stats Today's Range$3.78▼$4.0150-Day Range$3.14▼$4.4952-Week Range$2.90▼$7.75Volume137,610 shsAverage Volume202,846 shsMarket Capitalization$248.49 millionP/E RatioN/ADividend YieldN/APrice Target$10.44Consensus RatingModerate Buy Company Overview CAMP4 Therapeutics Corporation is a clinical-stage biotechnology company focused on developing medicines that increase the production of disease-relevant proteins by activating the expression of specific genes. The company’s approach is designed to address diseases caused by insufficient protein levels, including certain genetic disorders in which boosting activity from a functional gene copy may provide therapeutic benefit. CAMP4 uses its Regulatory Action Platform, or RAP, to identify regulatory elements that control RNA production and discover small-molecule compounds capable of increasing the expression of selected genes. Its programs are intended to work at the level of gene transcription and RNA regulation rather than by replacing defective genes or directly supplying missing proteins. The company’s lead program, CMP-CPS, is an orally administered small-molecule therapy designed to increase production of carbamoyl phosphate synthetase 1, an enzyme involved in the urea cycle. CAMP4 is investigating the program as a potential treatment for urea cycle disorders, including ornithine transcarbamylase deficiency. CAMP4 Therapeutics is headquartered in Cambridge, Massachusetts, and serves the biopharmaceutical market through the development of internally discovered therapeutics.AI Generated. May Contain Errors. Read More CAMP4 Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks60th Percentile Overall ScoreCAMP MarketRank™: 3.02129032258 of 5 starsCAMP4 Therapeutics scored higher than 60% of companies evaluated by MarketBeat, and ranked 385th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingCAMP4 Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on 1 strong buy rating, 8 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialCAMP4 Therapeutics has a consensus price target of $10.44, representing about 166.4% upside from its current price of $3.92.Amount of Analyst CoverageCAMP4 Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about CAMP4 Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for CAMP4 Therapeutics are expected to decrease in the coming year, from ($0.68) to ($0.75) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CAMP4 Therapeutics is -1.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CAMP4 Therapeutics is -1.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCAMP4 Therapeutics has a P/B Ratio of 3.84. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.02% of the float of CAMP4 Therapeutics has been sold short.Short Interest Ratio / Days to CoverCAMP4 Therapeutics has a short interest ratio ("days to cover") of 10.06, which indicates bearish sentiment.Change versus previous monthShort interest in CAMP4 Therapeutics has recently increased by 136.36%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCAMP4 Therapeutics does not currently pay a dividend.Dividend GrowthCAMP4 Therapeutics does not have a long track record of dividend growth. News and Social Media3.4 / 5News Sentiment0.38 News SentimentCAMP4 Therapeutics has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 8 news articles for CAMP4 Therapeutics this week, compared to 3 articles on an average week.Search Interest1 people have searched for CAMP on MarketBeat in the last 30 days. MarketBeat Follows1 people have added CAMP4 Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership2.9 / 5Insider TradingSelling Shares Cluster Insider Buying4 insiders have purchased shares of CAMP4 Therapeutics in the last three months. Multiple insiders buying is a strong bullish signal.Insider Buying vs. Insider SellingIn the past three months, CAMP4 Therapeutics insiders have sold 2,428.03% more of their company's stock than they have bought. Specifically, they have bought $99,051.00 in company stock and sold $2,504,037.00 in company stock.Percentage Held by Insiders21.69% of the stock of CAMP4 Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsCAMP4 Therapeutics has minimal institutional ownership at this time.Read more about CAMP4 Therapeutics' insider trading history. Receive CAMP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CAMP4 Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CAMP Stock News HeadlinesCAMP4 Therapeutics Corporation (NASDAQ:CAMP) Stock Has Average Target Price of $10.44 According to AnalystsOctober 30 at 3:16 AM | americanbankingnews.comCAMP4 Shares Rise After EU Clinical Trial Application ApprovalsOctober 27 at 7:33 PM | marketwatch.comFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.October 30 at 1:00 AM | Weiss Ratings (Ad)CAMP4 Therapeutics Receives Clinical Trial Application Approval for Phase 1/2 Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder in the European UnionOctober 27 at 8:00 AM | globenewswire.comRaymond James initiates coverage of Camp4 Therapeutics with strong buyOctober 23, 2026 | msn.comNeedham & Co Initiates Coverage on CAMP4 Therapeutics With Buy Rating, $8 Price TargetOctober 15, 2026 | marketscreener.comMCAMP4 to Participate in Chardan’s 10th Annual Healthcare ConferenceOctober 14, 2026 | markets.businessinsider.comCAMP4 to Participate in Chardan's 10th Annual Healthcare ConferenceOctober 14, 2026 | globenewswire.comSee More Headlines CAMP Stock Analysis - Frequently Asked Questions How have CAMP shares performed this year? CAMP4 Therapeutics' stock was trading at $6.0850 at the start of the year. Since then, CAMP stock has decreased by 35.6% and is now trading at $3.9210. How were CAMP4 Therapeutics' earnings last quarter? CAMP4 Therapeutics Corporation (NASDAQ:CAMP) issued its earnings results on Thursday, August, 13th. The Wireless communications provider reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.24) by $0.34. The Wireless communications provider earned $1.78 million during the quarter. CAMP4 Therapeutics had a negative net margin of 2,543.74% and a negative trailing twelve-month return on equity of 252.79%. When did CAMP4 Therapeutics' stock split? CAMP4 Therapeutics's stock reverse split on the morning of Friday, February 2nd 2024.The 1-23 reverse split was announced on Friday, February 2nd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 2nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. Does CAMP4 Therapeutics have any subsidiaries? The following companies are subsidiaries of CAMP4 Therapeutics: LoJack, Gulfstream Telematics, SmartLink Radio Networks, CalAmp Wireless Networks Inc., Skybility, Boisen S.A., CalAmp Importation and Leasing of Tracking Equipment Ltd., and others. When did CAMP4 Therapeutics IPO? CAMP4 Therapeutics (CAMP) raised $102 million in an initial public offering on Friday, October 11th 2024. The company issued 6,820,000 shares at $14.00-$16.00 per share. How do I buy shares of CAMP4 Therapeutics? Shares of CAMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CAMP4 Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that CAMP4 Therapeutics investors own include Inseego (INSG), Union Pacific (UNP), Intel (INTC), Zimmer Biomet (ZBH), Tesla (TSLA), NVIDIA (NVDA) and Advanced Micro Devices (AMD). Company Calendar Last Earnings8/13/2026Today10/30/20263rd Annual Guggenheim Healthcare Innovation Conference11/09/20262026 Stifel Healthcare Conference11/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 CAMP's financial health is in the Green zone, according to TradeSmith. CAMP has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:CAMP CIK1736730 Webwww.calamp.com Phone(949) 600-5600Fax805-856-3857Employees644Year Founded1981Price Target and Rating Average Price Target for CAMP4 Therapeutics$10.44 High Price Target$15.00 Low Price Target$6.00 Potential Upside/Downside+163.1%Consensus RatingModerate Buy Rating Score (0-4)2.82 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($2.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$80.40 million Net Margins-2,543.74% Pretax Margin-2,543.74% Return on Equity-252.79% Return on Assets-85.65% Debt Debt-to-Equity RatioN/A Current Ratio4.70 Quick Ratio4.70 Sales & Book Value Annual Sales$3.50 million Price / Sales71.18 Cash FlowN/A Price / Cash FlowN/A Book Value$1.02 per share Price / Book3.89Miscellaneous Outstanding Shares62,750,000Free Float49,142,000Market Cap$249.12 million OptionableNo Data Beta0.27 Social Links Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:CAMP) was last updated on 10/30/2026 by MarketBeat.com Staff. From Our PartnersA free stock pick, from me to youElon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Withou...Behind the Markets | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredElon Musk about to bankrupt Amazon, Microsoft & Google?Jeff Brown, the former tech executive who called the rise of Bitcoin, Tesla, and Nvidia years early, is tracki...Brownstone Research | SponsoredTwo charts tell you the future…Gold miners are posting record cash flows, outperforming every other sector, yet mining still makes up just 1%...Golden Portfolio | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | SponsoredExecutive Order 14241 Unleashes Trump’s New DollarA landmark executive order, 14241, is reportedly set to reshape how Americans use money starting this December...Porter & Company | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CAMP4 Therapeutics Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share CAMP4 Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
